Valneva’s shot is the only candidate in clinical trials in Europe that uses a technology involving an inactivated version of the whole virus it’s targeting
The first participant in its phase three trials will be dosed this week. If successful, it will probably be used as a winter booster for older British adults

Published: 7:59pm, 29 Apr, 2021

Updated: 7:59pm, 29 Apr, 2021